Trial Condition(s):

Multiple Sclerosis

Medication usage and Patient Reported Outcomes evaluation via myBETAapp in patients with multiple sclerosis treated with Betaferon: a pilot study (PROmyBETAapp)

Bayer Identifier:

18462

ClinicalTrials.gov Identifier:

NCT03134573

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness tracker in the myBETAapp will be observed for 3 months.

Inclusion Criteria
-Patients aged ≥ 18 years. 
-Patients on treatment with Betaferon (every Betaferon box contains a “Mixject” number, which is a product specific number unrelated to the study. Only patients prescribed Betaferon for their MS will be able to use the myBETAapp and participate in the study). 
-Patients must be using the myBETAapp. 
-Electronic informed consent must be obtained.
Exclusion Criteria
-There are no exclusion criteria for participation in this study.

Trial Summary

Enrollment Goal
96
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, Germany

Status
Completed
 

Trial Design